Targeting fusion-derived cancer testis antigens such as NYESO-1 and MAGEA-4 has shown benefits in limited sarcomas such as synovial sarcoma and Myxoid/Round Cell Liposarcoma (71–73). Here, MAGEA4 is linked to synovial sarcoma.